Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
BEIJING MEIKANG GENO-IMMUNE BIOTECHNOLOGY CO., LTD. has 4 pending office actions in Biotechnology & Pharmaceuticals. These matters are distributed among 4 distinct examiners and 3 distinct art units. ROGERS, ERIC JASON is the busiest examiner, with 1 pending office action. The concentration of 4 pending office actions in 3 distinct art units suggests some overlap in the technical subject matter.
The company's 4 pending office actions are being reviewed by 4 distinct examiners, ensuring that no single official dominates the current prosecution. ROGERS, ERIC JASON is the busiest examiner with 1 pending office action, which is the standard workload for this portfolio. Because the actions are spread across 3 distinct art units, there is a moderate level of technical focus.
This distribution across 3 distinct art units requires the company to manage three different sets of examiner expectations while pursuing its Biotechnology & Pharmaceuticals patents. Each official is responsible for exactly one pending action, ensuring independent reviews for each application. Practitioners should monitor the 3 distinct art units for consistent application of standards. A coordinated strategy is necessary to address the unique procedural nuances of each individual group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
| VISONE, THOMAS J | 1 | 55.6% | +40.2% |
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705431 | TISSUE-SPECIFIC PROMOTER AND USE THEREOF | ROGERS, ERIC JASON | — |
| 18557159 | MYELOID-SPECIFIC PROMOTER AND USE THEREOF | VISONE, THOMAS J | — |
| 18557147 | RECOMBINANT COAGULATION FACTOR VIII AND USE THEREOF | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705431 | TISSUE-SPECIFIC PROMOTER AND USE THEREOF | ROGERS, ERIC JASON | — |
| 18557159 | MYELOID-SPECIFIC PROMOTER AND USE THEREOF | VISONE, THOMAS J | — |
| 18557147 | RECOMBINANT COAGULATION FACTOR VIII AND USE THEREOF | BEANE, RANDALL L | — |
| 17604360 | CYBB LENTIVIRAL VECTOR, LENTIVIRAL VECTOR-TRANSDUCED STEM CELL, AND PREPARATION METHOD AND APPLICATION THEREOF | JOHNSON, ALLISON MARIE | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| 1672 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705431 | TISSUE-SPECIFIC PROMOTER AND USE THEREOF | ROGERS, ERIC JASON | 1638 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18557159 | MYELOID-SPECIFIC PROMOTER AND USE THEREOF | VISONE, THOMAS J | 1672 | §102§103§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18557147 | RECOMBINANT COAGULATION FACTOR VIII AND USE THEREOF | BEANE, RANDALL L | 1654 | §102§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 17604360 | CYBB LENTIVIRAL VECTOR, LENTIVIRAL VECTOR-TRANSDUCED STEM CELL, AND PREPARATION METHOD AND APPLICATION THEREOF | JOHNSON, ALLISON MARIE | 1638 | §103 | Final Rejection | — | Pending | Oct 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBEIJING MEIKANG GENO-IMMUNE BIOTECHNOLOGY CO., LTD. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Eric Jason Rogers has the most, with 1 of BEIJING MEIKANG GENO-IMMUNE BIOTECHNOLOGY CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
